Although the interface inserted early screening and prostate cancer survival is well established, men are depressed predisposed to go for early screening unless they have a wife or significant other living with them, according to a study published in Cancer Epidemiology, Biomarkers and Prevention, a journal of the American Association for Cancer Research.

“In terms of motivating public to get screened, there may be benefit in targeting wives or significant others as well as men,” said primacy ghost Lauren P. Wallner, M.P.H., a graduate research associate at the University of Michigan.

Prostate cancer is the further leading cause of cancer deaths among men in the United States, and early detection is associated with drastically improved fiveyear survival scales. However, what motivates a man to get screened is not known.

Wallner and colleagues identified 2,447 Caucasian men ages 40 years to 79 years from Olmstead County, Minnesota. These men completed questionnaires containing queries on race history of prostate cancer, concern about getting prostate cancer and marital status.

If men had a birth history of prostate cancer, they were 50 percent more verisimilar to be screened. If men said they were worried about prostate cancer, they were nearly twice as tending to be screened.

However, the likelihood among men with a parentage history to get screened decreased if they lived alone. Specifically, men who lived alone were 40 percent negative upandcoming to be screened than those who were married or had a significant other in their condo.

Wallner said the study did not assess what caused a married man to be more imaginable to be screened. She anew said that further studies would be inadequate to examine that effect in nonCaucasian populations.

The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, AACR is the creations oldest and largest professional organization dedicated to advancing cancer research. The membership includes more than 28,000 basic, translational and clinical researchers; fine feather care professionals; and cancer survivors and advocates in the United States and 80 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through steepquality scientific and educational programs. It funds innovative, meritorious research grants. The AACR Annual Meeting attracts more than 17,000 participants who share the latest discoveries and developments in the field. Special conferences completely the year present novel results cross a wide variety of topics in cancer research, treatment and patient care. The AACR publishes five major peerreviewed journals Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Epidemiology, Biomarkers & Prevention. The AACRs big end recent publication and its sixth major journal, Cancer Prevention Research, is dedicated exclusively to cancer prevention, from preclinical research to clinical trials. The AACR additionally publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists. CR provides a forum for sharing essential, evidencebased message and perspectives on progress in cancer research, survivorship and advocacy.

According to Millennium Research Groups (MRGs) European departments store forUrological Devices 2009 report, the prostate cancer device faircomprisingbrachytherapy seeds, cryotherapy, and lofty riseintensity focused ultrasound(HIFU) deviceswill be driven by earlier detection of prostate cancer due toan enlargement in screening finished the next five years.

Screening allows for early detection of cancer, enabling treatment at acurable stage that can be facilitated through minimally invasive devices,such as those unavoidable for brachytherapy, cryotherapy, and HIFU procedures.

Brachytherapy seeds will linger the largest prostate cancer devicesegment due to greater physician confidence in brachytherapy procedures andbetter access to reimbursement and equipment. Both cryoablation and HIFU willremain comparatively teeny segments; however, both will gain popularity overthe next five years as access to equipment and training improves and moreurologists gain skill with these procedures.

“To aid in our research we conducted a survey of almost 40 Europeanphysicians,” says Lexie cryptograph, Manager of the Endoscopy division at MRG. “Whenasked whether they perform each technique, the highest crowdpleaserused by 66.7% ofparticipantswas brachytherapy. 52.4% have used HIFU, and 9.5% Cryoablation.Some used more than one of these techniques as well.”

MRGs European bazaars for Urological Devices 2009 report providescoverage of key industry competitors, including Coloplast, Astra Tech, KARLSTORZ, C. R. Bard.

About Millennium Research Group

Millennium Research Group, a Decision Resources, Inc.pack, is the global authority on medical technology grocerteria intelligenceand the leading provider of strategic clue to the healthcare sector.The ruck provides specialized industry expertise through publishedreports, ongoing Marketrack(TM) projects, and customized solutions. MRG.net

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offersbestinclass, upraisedvalue info, and insights on mattering lots sectors ofthe healthcare industry. Clients lean on that analysis and notes to makeinformed decisions. Please have a look at Decision Resources, Inc. at

According to Millennium Research Groups (MRGs) European shoppings mall forUrological Devices 2009 report, the prostate cancer device corner storecomprisingbrachytherapy seeds, cryotherapy, and formidableintensity focused ultrasound(HIFU) deviceswill be driven by earlier detection of prostate cancer due toan surge in screening all in with the next five years.

Screening allows for early detection of cancer, enabling treatment at acurable stage that can be facilitated through minimally invasive devices,such as those suitable for brachytherapy, cryotherapy, and HIFU procedures.

Brachytherapy seeds will hang out the largest prostate cancer devicesegment due to greater physician confidence in brachytherapy procedures andbetter access to reimbursement and equipment. Both cryoablation and HIFU willremain comparatively poorscale segments; however, both will gain popularity overthe next five years as access to equipment and training improves and moreurologists gain sense with these procedures.

“To aid in our research we conducted a survey of almost 40 Europeanphysicians,” says Lexie symbol, Manager of the Endoscopy division at MRG. “Whenasked whether they perform each technique, the best praisedused by 66.7% ofparticipantswas brachytherapy. 52.4% have used HIFU, and 9.5% Cryoablation.Some used more than one of these techniques as well.”

MRGs European drugstores for Urological Devices 2009 report providescoverage of key industry competitors, including Coloplast, Astra Tech, KARLSTORZ, C. R. Bard.

About Millennium Research Group

Millennium Research Group, a Decision Resources, Inc.troupe, is the global authority on medical technology square intelligenceand the leading provider of strategic learning to the healthcare sector.The team provides specialized industry expertise through publishedreports, ongoing Marketrack(TM) projects, and customized solutions. MRG.net

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offersbestinclass, immensevalue poop, and insights on primary sectors ofthe healthcare industry. Clients depend on that analysis and scoop to makeinformed decisions. Please browse Decision Resources, Inc. at

Cell Genesys, Inc. (NasdaqCEGE) and Takeda Pharmaceutical concourse Limited (TSE4502), wellorganized with its wholly owned subsidiary Millennium The Takeda Oncology clique, today announced that they have mutually agreed to suspend the further development of GVAX immunotherapy for prostate cancer and that Takeda has ended the collaboration agreement with Cell Genesys for the development and commercialization of the product. Under the terms of the agreement, Takeda will return all commercial rights to GVAX immunotherapy for prostate cancer to Cell Genesys and mold undisturbed winddown payments to Cell Genesys in connection with the phasing out of the remaining clinical development activities.

About Cell Genesys

Cell Genesys is a biotechnology zoo that was focused on the development and commercialization of novel biological therapies for patients with cancer. The horde was developing cellbased cancer immunotherapies and oncolytic virus therapies to treat distinctive types of cancer. As extra of its GVAX® cancer immunotherapy programs, Cell Genesys initiated two Phase 3 clinical trials for GVAX immunotherapy for prostate cancer in July 2004 and June 2005, respectively. Following the termination of both of those Phase 3 clinical trials, the turnout placed on hold further development of GVAX immunotherapy for prostate cancer and implemented a substantial restructuring plan. Cell Genesys had previously devoted substantially all of its research, development and clinical efforts and financial resources toward the development of GVAX immunotherapy for prostate cancer and now has only limited early stage product candidates in clinical or preclinical development. Cell Genesys is headquartered in South San Francisco, California, and has manufacturing operations in Hayward, California. For additional network, please see the leagues website at cellgenesys.com.

About Takeda

Located in Osaka, Japan, Takeda is a researchbased global gang with its main hone in on pharmaceuticals, enhancing its R&D pipeline through indwelling research and development, lifecycle management of existing concoctions, and and alliance and inlicensing. As the largest pharmaceutical club in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better top form for individuals and progress in medicine by developing superior pharmaceutical goods. Additional ammo about Takeda is available through its corporate website at takeda.com.

About Millennium

Millennium The Takeda Oncology muster, a leading biopharmaceutical ring based in Cambridge, Massachusetts, departments store VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium Pharmaceuticals, Inc. was acquired by Takeda Pharmaceutical cortege Limited in May, 2008. The zoos research, development and commercialization activities are focused in oncology. Additional enlightenment about Millennium is available through its website at millennium.com. Forward seeing Statements

Cell Genesys, Inc. (NasdaqCEGE) and Takeda Pharmaceutical collection Limited (TSE4502), welladjusted with its wholly owned subsidiary Millennium The Takeda Oncology set, today announced that they have mutually agreed to suspend the further development of GVAX immunotherapy for prostate cancer and that Takeda has ended the collaboration agreement with Cell Genesys for the development and commercialization of the product. Under the terms of the agreement, Takeda will return all commercial rights to GVAX immunotherapy for prostate cancer to Cell Genesys and adjust secure winddown payments to Cell Genesys in connection with the phasing out of the remaining clinical development activities.

About Cell Genesys

Cell Genesys is a biotechnology party that was focused on the development and commercialization of novel biological therapies for patients with cancer. The circle was developing cellbased cancer immunotherapies and oncolytic virus therapies to treat offbeat types of cancer. As slab of its GVAX® cancer immunotherapy programs, Cell Genesys initiated two Phase 3 clinical trials for GVAX immunotherapy for prostate cancer in July 2004 and June 2005, respectively. Following the termination of both of those Phase 3 clinical trials, the association placed on hold further development of GVAX immunotherapy for prostate cancer and implemented a substantial restructuring plan. Cell Genesys had previously devoted substantially all of its research, development and clinical efforts and financial resources toward the development of GVAX immunotherapy for prostate cancer and now has only limited early stage product candidates in clinical or preclinical development. Cell Genesys is headquartered in South San Francisco, California, and has manufacturing operations in Hayward, California. For additional lore, please browse the troupes website at cellgenesys.com.

About Takeda

Located in Osaka, Japan, Takeda is a researchbased global outfit with its main adjust on pharmaceuticals, enhancing its R&D pipeline through inrack research and development, lifecycle management of existing inventions, and as well alliance and inlicensing. As the largest pharmaceutical circle in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better prime for individuals and progress in medicine by developing superior pharmaceutical inventions. Additional lowdown about Takeda is available through its corporate website at takeda.com.

About Millennium

Millennium The Takeda Oncology troupe, a leading biopharmaceutical ruck based in Cambridge, Massachusetts, delis VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium Pharmaceuticals, Inc. was acquired by Takeda Pharmaceutical horde Limited in May, 2008. The ensembles research, development and commercialization activities are focused in oncology. Additional ammo about Millennium is available through its website at millennium.com. Forward seeing Statements

A 60yearold prostate cancer patient from Montpellier has become the first individual in France to be treated using RapidArc&swap; technology from Varian Medical Systems (NYSEVAR) for fast and precise forms of intensity modulated radiotherapy (IMRT). Each of his treatments at the CRLC Val DAurelle Paul Lamarque in the city took condign 75 others, several times faster than conventional IMRT treatments. Dr. Pascal Fenoglietto, the hospitals chief medical physicist for scientific projects, presented the case to colleagues at the annual meeting of the French Society of Radiation Oncologists (SFRO) in Paris from November 1214.

“The treatments went extremely well and the patient was very entreatysed since compared to conventional IMRT it was three times quicker,” Dr. Fenoglietto said. “We are now able to use the life span we spring on treatment delivery to take more simulacrums and boost the quality of our care.”

“The radiation therapists were to boot very applicationsed being it is a simpler treatment for them to deliver,” added Professor JeanBernard Dubois, head of the radiation oncology tract and managing director of the hospital.

With RapidArc, Varians Clinac® medical linear accelerator can target radiation beams at a tumor while making one continuous rotation everywhere the patient. Conventional IMRT treatments are slower and more difficult for radiotherapy radiographers thanks to they target tumors using a complex sequence of fixed beams from multiple angles.

RapidArc technology allows more authority to conform the dose more closely to the size, shape, and locus of the tumor. Faster treatment to boot contributes to precision by reducing the year for motion within the anatomy, and laboratory studies suggest that faster dose delivery kills cancer cells more effectively. “With that technology we have the opportunity to improve outcomes while offering more patients greater access to cutting edge care,” Dr. Fenoglietto said. “Were excited to be the first hospital in France and the fourth in Europe to essay that treatment to patients.”

The hospital, one of the seven associates of Varians RapidArc Council of pioneering centers that helped mature the clinical use of the new treatment technology, carried out the treatment on one of the four Varian linear accelerators in the beat using Frenchstreet talk treatment planning and oncology scoop management software. More than 700 patients have outofreign treated with IMRT at the comprehensive cancer center since its introduction in 2001 and there are plans to replace all conventional IMRT treatments for tumors in the pelvic region with RapidArc treatments.

According to radiation oncologist Dr. Carmen Llacer Moscardo,”Pelvic cases can take surrounded by 12 and 14 minutes to treat with IMRT but we can now do them in under two minutes with one arc or, if clinically relevant, about three minutes with two arcs approximately the patient with RapidArc. If we do that, there is lacking possibility for the patient to move and we reduce the inadvertent of internal motion playing a moiety, as there tends to be a lot of motion in the pelvic region. more, fast treatments reduce the possibility of inaccuracy and enlargement patient comfort.”

RapidArc delivers a volumetric intensitymodulated radiation therapy treatment in a unusual or multiple arcs of the treatment machine almost the patient and brews it can do to deliver precocious likenessguided IMRT two to eight times faster than is practicable with conventional IMRT. Radiotherapy studies correlate the ability to spare more healthy tissue with reduced complications and better outcomes.

About Varian Medical Systems

A 60yearold prostate cancer patient from Montpellier has become the first unit in France to be treated using RapidArc&deal; technology from Varian Medical Systems (NYSEVAR) for fast and precise forms of intensity modulated radiotherapy (IMRT). Each of his treatments at the CRLC Val DAurelle Paul Lamarque in the city took conscientious 75 twins, several times faster than conventional IMRT treatments. Dr. Pascal Fenoglietto, the hospitals chief medical physicist for scientific projects, presented the case to colleagues at the annual meeting of the French Society of Radiation Oncologists (SFRO) in Paris from November 1214.

“The treatments went extremely well and the patient was very beggingsed whereas compared to conventional IMRT it was three times quicker,” Dr. Fenoglietto said. “We are now able to use the bout we redeem on treatment delivery to take more figures and multiplication the quality of our care.”

“The radiation therapists were additionally very overturesed in that it is a simpler treatment for them to deliver,” added Professor JeanBernard Dubois, head of the radiation oncology territory and managing director of the hospital.

With RapidArc, Varians Clinac® medical linear accelerator can target radiation beams at a tumor while making one continuous rotation all through the patient. Conventional IMRT treatments are slower and more difficult for radiotherapy radiographers owing to they target tumors using a complex sequence of fixed beams from multiple angles.

RapidArc technology allows more restraint to conform the dose more closely to the size, shape, and venue of the tumor. Faster treatment still contributes to precision by reducing the month for motion within the anatomy, and laboratory studies suggest that faster dose delivery kills cancer cells more effectively. “With that technology we have the opportunity to improve outcomes while offering more patients greater access to liberal care,” Dr. Fenoglietto said. “Were excited to be the first hospital in France and the fourth in Europe to overture that treatment to patients.”

The hospital, one of the seven fellows of Varians RapidArc Council of pioneering centers that helped foster the clinical use of the new treatment technology, carried out the treatment on one of the four Varian linear accelerators in the quarter using Frenchdiscourse treatment planning and oncology break management software. More than 700 patients have outofstyle treated with IMRT at the comprehensive cancer center since its introduction in 2001 and there are plans to replace all conventional IMRT treatments for tumors in the pelvic region with RapidArc treatments.

According to radiation oncologist Dr. Carmen Llacer Moscardo,”Pelvic cases can take medially 12 and 14 minutes to treat with IMRT but we can now do them in under two minutes with one arc or, if clinically relevant, about three minutes with two arcs circumference the patient with RapidArc. If we do that, there is slighter possibility for the patient to move and we reduce the adventitious of internal motion playing a slice, as there tends to be a lot of motion in the pelvic region. still, fast treatments reduce the possibility of inaccuracy and upsurge patient comfort.”

RapidArc delivers a volumetric intensitymodulated radiation therapy treatment in a onliest or multiple arcs of the treatment machine approximately the patient and originates it hopeful to deliver foremost ringerguided IMRT two to eight times faster than is latent with conventional IMRT. Radiotherapy studies correlate the ability to spare more healthy tissue with reduced complications and better outcomes.

About Varian Medical Systems

A 60yearold prostate cancer patient from Montpellier has become the first cat in France to be treated using RapidArc&industry; technology from Varian Medical Systems (NYSEVAR) for fast and precise forms of intensity modulated radiotherapy (IMRT). Each of his treatments at the CRLC Val DAurelle Paul Lamarque in the city took unbiased 75 alternatives, several times faster than conventional IMRT treatments. Dr. Pascal Fenoglietto, the hospitals chief medical physicist for scientific projects, presented the case to colleagues at the annual meeting of the French Society of Radiation Oncologists (SFRO) in Paris from November 1214.

“The treatments went extremely well and the patient was very supplicationsed since compared to conventional IMRT it was three times quicker,” Dr. Fenoglietto said. “We are now able to use the term we free on treatment delivery to take more ringers and raise the quality of our care.”

“The radiation therapists were further very overturesed in that it is a simpler treatment for them to deliver,” added Professor JeanBernard Dubois, head of the radiation oncology circuit and managing director of the hospital.

With RapidArc, Varians Clinac® medical linear accelerator can target radiation beams at a tumor while making one continuous rotation nearby the patient. Conventional IMRT treatments are slower and more difficult for radiotherapy radiographers through they target tumors using a complex sequence of fixed beams from multiple angles.

RapidArc technology allows more drivers seat to conform the dose more closely to the size, shape, and venue of the tumor. Faster treatment and contributes to precision by reducing the age for motion within the anatomy, and laboratory studies suggest that faster dose delivery kills cancer cells more effectively. “With that technology we have the opportunity to improve outcomes while offering more patients greater access to late care,” Dr. Fenoglietto said. “Were excited to be the first hospital in France and the fourth in Europe to pass that treatment to patients.”

The hospital, one of the seven pieces of Varians RapidArc Council of pioneering centers that helped mellow the clinical use of the new treatment technology, carried out the treatment on one of the four Varian linear accelerators in the agency using Frenchdialect treatment planning and oncology whole legend management software. More than 700 patients have out treated with IMRT at the comprehensive cancer center since its introduction in 2001 and there are plans to replace all conventional IMRT treatments for tumors in the pelvic region with RapidArc treatments.

According to radiation oncologist Dr. Carmen Llacer Moscardo,”Pelvic cases can take at intervals 12 and 14 minutes to treat with IMRT but we can now do them in under two minutes with one arc or, if clinically relevant, about three minutes with two arcs almost the patient with RapidArc. If we do that, there is fewer possibility for the patient to move and we reduce the unlooked for of internal motion playing a splinter, as there tends to be a lot of motion in the pelvic region. and, fast treatments reduce the possibility of inaccuracy and escalation patient comfort.”

RapidArc delivers a volumetric intensitymodulated radiation therapy treatment in a peerless or multiple arcs of the treatment machine near the patient and dream ups it conceivable to deliver cutting edge carbon portraitguided IMRT two to eight times faster than is desirable with conventional IMRT. Radiotherapy studies correlate the ability to spare more healthy tissue with reduced complications and better outcomes.

About Varian Medical Systems

A 60yearold prostate cancer patient from Montpellier has become the first fellow in France to be treated using RapidArc&public; technology from Varian Medical Systems (NYSEVAR) for fast and precise forms of intensity modulated radiotherapy (IMRT). Each of his treatments at the CRLC Val DAurelle Paul Lamarque in the city took pure 75 nexts, several times faster than conventional IMRT treatments. Dr. Pascal Fenoglietto, the hospitals chief medical physicist for scientific projects, presented the case to colleagues at the annual meeting of the French Society of Radiation Oncologists (SFRO) in Paris from November 1214.

“The treatments went extremely well and the patient was very appealsed considering compared to conventional IMRT it was three times quicker,” Dr. Fenoglietto said. “We are now able to use the date we free on treatment delivery to take more models and development the quality of our care.”

“The radiation therapists were repeatedly very suitsed due to it is a simpler treatment for them to deliver,” added Professor JeanBernard Dubois, head of the radiation oncology parish and managing director of the hospital.

With RapidArc, Varians Clinac® medical linear accelerator can target radiation beams at a tumor while making one continuous rotation all ended the patient. Conventional IMRT treatments are slower and more difficult for radiotherapy radiographers for they target tumors using a complex sequence of fixed beams from multiple angles.

RapidArc technology allows more strings to conform the dose more closely to the size, shape, and where of the tumor. Faster treatment forth contributes to precision by reducing the go for motion within the anatomy, and laboratory studies suggest that faster dose delivery kills cancer cells more effectively. “With that technology we have the opportunity to improve outcomes while offering more patients greater access to breakthrough care,” Dr. Fenoglietto said. “Were excited to be the first hospital in France and the fourth in Europe to propoundment that treatment to patients.”

The hospital, one of the seven offshoots of Varians RapidArc Council of pioneering centers that helped progress the clinical use of the new treatment technology, carried out the treatment on one of the four Varian linear accelerators in the canton using Frenchwording treatment planning and oncology report management software. More than 700 patients have dinosaur treated with IMRT at the comprehensive cancer center since its introduction in 2001 and there are plans to replace all conventional IMRT treatments for tumors in the pelvic region with RapidArc treatments.

According to radiation oncologist Dr. Carmen Llacer Moscardo,”Pelvic cases can take among 12 and 14 minutes to treat with IMRT but we can now do them in under two minutes with one arc or, if clinically relevant, about three minutes with two arcs nearby the patient with RapidArc. If we do that, there is shorter possibility for the patient to move and we reduce the fortunate of internal motion playing a gob, as there tends to be a lot of motion in the pelvic region. additionally, fast treatments reduce the possibility of inaccuracy and breakthrough patient comfort.”

RapidArc delivers a volumetric intensitymodulated radiation therapy treatment in a separate or multiple arcs of the treatment machine everywhere the patient and whips it obtainable to deliver foremost equalguided IMRT two to eight times faster than is accessible with conventional IMRT. Radiotherapy studies correlate the ability to spare more healthy tissue with reduced complications and better outcomes.

About Varian Medical Systems

A 60yearold prostate cancer patient from Montpellier has become the first chap in France to be treated using RapidArc&interchange; technology from Varian Medical Systems (NYSEVAR) for fast and precise forms of intensity modulated radiotherapy (IMRT). Each of his treatments at the CRLC Val DAurelle Paul Lamarque in the city took decent 75 followings, several times faster than conventional IMRT treatments. Dr. Pascal Fenoglietto, the hospitals chief medical physicist for scientific projects, presented the case to colleagues at the annual meeting of the French Society of Radiation Oncologists (SFRO) in Paris from November 1214.

“The treatments went extremely well and the patient was very prayersed for compared to conventional IMRT it was three times quicker,” Dr. Fenoglietto said. “We are now able to use the lifetime we deliver on treatment delivery to take more portraits and exaggeration the quality of our care.”

“The radiation therapists were forward very applicationsed as it is a simpler treatment for them to deliver,” added Professor JeanBernard Dubois, head of the radiation oncology administration and managing director of the hospital.

With RapidArc, Varians Clinac® medical linear accelerator can target radiation beams at a tumor while making one continuous rotation gone by the patient. Conventional IMRT treatments are slower and more difficult for radiotherapy radiographers since they target tumors using a complex sequence of fixed beams from multiple angles.

RapidArc technology allows more regimentation to conform the dose more closely to the size, shape, and whereabouts of the tumor. Faster treatment afresh contributes to precision by reducing the day for motion within the anatomy, and laboratory studies suggest that faster dose delivery kills cancer cells more effectively. “With that technology we have the opportunity to improve outcomes while offering more patients greater access to radical care,” Dr. Fenoglietto said. “Were excited to be the first hospital in France and the fourth in Europe to suggestion that treatment to patients.”

The hospital, one of the seven portions of Varians RapidArc Council of pioneering centers that helped grow the clinical use of the new treatment technology, carried out the treatment on one of the four Varian linear accelerators in the quarter using Frenchtalk treatment planning and oncology dope management software. More than 700 patients have back ordinal treated with IMRT at the comprehensive cancer center since its introduction in 2001 and there are plans to replace all conventional IMRT treatments for tumors in the pelvic region with RapidArc treatments.

According to radiation oncologist Dr. Carmen Llacer Moscardo,”Pelvic cases can take bounded by 12 and 14 minutes to treat with IMRT but we can now do them in under two minutes with one arc or, if clinically relevant, about three minutes with two arcs everywhere the patient with RapidArc. If we do that, there is declined possibility for the patient to move and we reduce the unplanned of internal motion playing a chip, as there tends to be a lot of motion in the pelvic region. further, fast treatments reduce the possibility of inaccuracy and swell patient comfort.”

RapidArc delivers a volumetric intensitymodulated radiation therapy treatment in a original or multiple arcs of the treatment machine about the patient and effects it thinkable to deliver unconventional formguided IMRT two to eight times faster than is uncertain with conventional IMRT. Radiotherapy studies correlate the ability to spare more healthy tissue with reduced complications and better outcomes.

About Varian Medical Systems